Mangosteen xanthones mitigate ovalbumin-induced airway inflammation in a mouse model of asthma

► Mangosteen xanthones reverse pathophysiological features of ovalbumin-induced mouse asthma model. ► Suppression of PI3K, Akt, and PTEN are involved in mitigating allergic asthma. ► The present results suggest potentials of α-and γ-mangostins as anti-asthmatic substances. α- and γ-Mangostin, which...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Food and chemical toxicology 2012-11, Vol.50 (11), p.4042-4050
Hauptverfasser: Jang, Ha-Young, Kwon, Ok-Kyoung, Oh, Sei-Ryang, Lee, Hyeong-Kyu, Ahn, Kyung-Seop, Chin, Young-Won
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:► Mangosteen xanthones reverse pathophysiological features of ovalbumin-induced mouse asthma model. ► Suppression of PI3K, Akt, and PTEN are involved in mitigating allergic asthma. ► The present results suggest potentials of α-and γ-mangostins as anti-asthmatic substances. α- and γ-Mangostin, which are the major xanthones purified from a Mangosteen, Garcinia mangostana Linn., exhibit a wide range of anticancer, antioxidant, and anti-inflammatory activities. Here, we assessed their therapeutic effects in a mouse model of ovalbumin (OVA)-induced allergic asthma. Animals were treated with α- and γ-mangostins orally for 3days at doses of 10 and 30mg/kg daily, 1h before the OVA challenge. Administration of α- and γ-mangostins significantly reduced the major pathophysiological features of allergic asthma, including inflammatory cell recruitment into the airway, airway hyperresponsiveness (AHR), and increased levels of Th2 cytokines. In addition, α- and γ-mangostins attenuated the increases in phosphoinositide 3-kinase (PI3K) activity, phosphorylation of Akt, and NF-κB in nuclear protein extracts after OVA challenge. In conclusion, α- and γ-mangostin may have therapeutic potential for the treatment of allergic asthma.
ISSN:0278-6915
1873-6351
DOI:10.1016/j.fct.2012.08.037